Sanofi and Regeneron eye challenge to Merck & Co in first li...

Sanofi and Regeneron could mount a challenge to Merck & Co’s Keytruda in untreated advanced lung cancer with their cancer immunotherapy latecomer Libtayo following new phase 3 results. 

Sanofi links with Luminostics on smartphone coronavirus test

Sanofi and GSK join forces on coronavirus vaccine

As the world waits with bated breath for a coronavirus vaccine, two of the world’s biggest vaccine manufacturers, Sanofi and GSK, have announced they are teaming up to develop an adjuvanted cand

EMA won't clear chloroquine for COVID-19 without trial data

The European drugs regulator has stopped short of granting widespread use of the drug chloroquine against COVID-19, days after the FDA said it could be used under emergency measures to figh

GSK eyes nasal polyps use for Nucala after trial success

GlaxoSmithKline is eyeing another indication for its Nucala (mepolizumab) biologic drug after a phase 3 trial in inflammation caused by nasal polyps hit its targets, bringing it into compet

Sanofi begins trial of Kevzara against COVID-19 complication...

Sanofi and Regeneron are throwing an already-approved drug at COVID-19, testing Kevzara (sarilumab) in patients hospitalised with severe disease.